Femasys Inc 8-K, filed Dec 21, 2022
Femasys Inc (FEMY)
8-K
2022-12-21
For: 2022-12-19
View Original
Added on
April 06, 2026
About this 8-K
Femasys Inc filed this 8-K on December 21, 2022, reporting on events of December 19, 2022.
Items reported
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 19, 2022
(Exact name of registrant as specified in its charter)
|
|
|
|
||
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
(770 ) 500-3910
(Registrant’s telephone number, including area code)
n/a
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instructions A.2. below):
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Exchange Act:
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange
on which registered
|
||
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
| Item 8.01 |
Other Events
|
On December 19, 2022, Femasys Inc. (the “Company”) announced the commercial availability of its FemCath intrauterine device. A copy of the press release is being
furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
| Item 9.01 |
Financial Statements and Exhibits.
|
(d) Exhibits
|
Exhibit
No.
|
Description
|
|
|
Press Release of Femasys Inc. dated December 19, 2022.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Femasys Inc.
|
||
|
By:
|
/s/ Kathy Lee-Sepsick
|
|
|
Names: Kathy Lee-Sepsick
|
||
|
Title: Chief Executive Officer
|
||
| Date: December 21, 2022 | ||
Exhibit 99.1
Femasys Inc. Announces Commercial Availability of its FemCath Intrauterine Device
--FemCath™ is the first FDA-cleared intrauterine catheter that allows for selective evaluation of a fallopian tube with
contrast --
-- FemCath is used in conjunction with FemVue as a baseline diagnostic
test for infertility --
ATLANTA, December 19, 2022 -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to
meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that its product, FemCath™, the first FDA-cleared intrauterine
catheter for selective tubal evaluation, is now commercially available. FemCath is used in conjunction with Femasys’ FemVue device for an ultrasound-based diagnostic test as part of an infertility evaluation, which is essential prior to any
infertility treatment, including with Femasys’ other biomedical solution in development, FemaSeed®.
FemCath utilizes Femasys’ proprietary delivery platform, which involves placement of balloon technology close to the opening of a selected fallopian tube
for directed delivery. Femasys’ other biomedical solutions in development, FemaSeed® and FemBloc®, utilize the same delivery platform for directed delivery of other materials. In the case of FemaSeed, sperm is delivered
directly to the tube where conception occurs and for FemBloc, a proprietary biopolymer is delivered to both tubes for nonsurgical permanent birth control.
“This is one more important milestone reached this year as we continue to expand much needed options for women with our suite of innovative products,” said
Kathy Lee-Sepsick, founder, president and chief executive officer of Femasys. “We are encouraged to improve the options available for those struggling with infertility and expect if FemaSeed is approved to bring a solution to the front-end of
care. In the meantime, FemCath will provide another measure of incremental revenue for Femasys when used with FemVue for any conditions requiring tubal evaluation.”
About FemVue
FemVue is the first FDA-cleared product that creates natural saline and air contrast and enables safe, reliable, and real time evaluation of the fallopian
tubes with ultrasound. When performed with a uterine cavity assessment, a more comprehensive exam can be achieved from the comfort of the GYN’s office.
About FemaSeed
FemaSeed is a first-of-its-kind infertility solution in development for directional intrauterine insemination that delivers sperm
to the fallopian tube where conception occurs. It is intended to augment natural fertilization and provide a first-line treatment option for infertility.
About FemBloc
FemBloc is a first-of-its-kind, nonsurgical, in-office solution in development for permanent birth control. It is intended to be a
safer option for women by eliminating the need for anesthesia, incisions, and permanent implants. FemBloc has the potential to offer women a convenient and reliable alternative method of permanent birth control.
About Femasys
Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive,
in-office technologies for reproductive health. Its two lead product candidates are FemBloc® permanent birth control and FemaSeed® localized directional insemination for infertility. The Company’s products currently marketed
in the United States, include FemVue® for fallopian tube assessment by ultrasound, which can be used in conjunction with FemCath™, an intrauterine catheter for selective evaluation of the fallopian tubes, and FemCerv®,
an endocervical tissue sampler that is the first product of the technology platform for tissue sampling. To learn more, visit www.femasys.com or follow us on Twitter and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking
statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “potential,” ”hope,” or “continue” or the negative of these terms or other similar expressions, although
not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict
and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ
include, among others: our ability to develop and advance our current product candidates and programs into, and successfully initiate, enroll and complete, clinical trials; the ability of our clinical trials to demonstrate safety and effectiveness
of our product candidates and other positive results; estimates regarding the total addressable market for our product candidates; our business model and strategic plans for our products, technologies and business, including our implementation
thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2021 and other reports as filed with the SEC. Forward-looking statements contained in
this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.
Contacts:
Investors
Chuck Padala
LifeSci Advisors, LLC
917-741-7792
chuck@lifesciadvisors.com
Femasys Inc.
Investor Contact:
IR@femasys.com
Media
Media Contact:
Media@femasys.com